Notice of NIAID's Participation in PAR-19-158 "Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)"

Notice Number: NOT-AI-19-031

Key Dates
Release Date: January 8, 2019

Related Announcements

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)


The purpose of this Notice is to inform potential applicants that the National Institute of Allergy and Infectious Diseases (NIAID) will participate, effective immediately, in PAR-19-158 , “Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed). The following changes and updates are made to PAR-19-158  (shown in italics) to reflect NIAID’s participation in this FOA.

Part 1. Overview Information

Components of Participating Organizations

National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Environmental Health Sciences (NIEHS)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.286, 93.113, 93.273, 93.855, 93.866

Section I. Funding Opportunity Description

Institute statements of interest:

NIAID: Within the goals of this FOA, NIAID is particularly interested in the following areas:

  • Quantitative, predictive models of complex interactions of the immune system during development; in response to pathogens or vaccines; during the initiation, development and/or progression of immune-mediated diseases (i.e., allergy, asthma, autoimmune disease, solid organ or pancreatic islet beta cell transplant rejection); and/or for early stage development of interventions for immune-mediated diseases.
  • Novel bioengineering approaches, including imaging, for analysis of immune cell phenotype and function in response to infectious and/or immune-mediated diseases in target organs and tissues; for delivery of immunomodulatory agents, adjuvants, or antigens; or development and/or characterization of novel biomaterials with immunostimulatory/adjuvant properties.
  • Biodosimetry biomarkers, technologies and devices to inform triage and treatment strategies of large populations following a radiological or nuclear incident.
  • Home-based, self-administered tests for detection of HIV in the acute phase of infection.
  • Simple and accurate assay to quantify the persistent HIV reservoir.
  • In vitro tissue models for infectious diseases that mimic human biological structures, recapitulate pathophysiology, and incorporate components critical to pathogenesis and host response; these models could be simple enough for use in basic science or sufficiently robust for use in preclinical studies of candidate therapeutics or vaccines.
  • Multiplex integrated sample-to-answer platforms to rapidly diagnose infectious diseases and identify the causative pathogen and its drug sensitivities.

All other aspects of this FOA remain the unchanged.


Please direct all inquiries to:

Nancy Lewis Ernst, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-5076